Abiopharma

New Form 424B3 - GT Biopharma, Inc. Filed: 2025-07-03 AccNo: 0001641172-25-017705 Size: 482 KB

New Form 8-K - NorthView Acquisition Corp Filed: 2025-07-03 AccNo: 0001213900-25-061232 Size: 271 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

ImmunoPrecise - ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

New Form 4 - TENAX THERAPEUTICS, INC. Filed: 2025-07-03 AccNo: 0001654954-25-007739 Size: 8 KB

New Form 4 - TENAX THERAPEUTICS, INC. Filed: 2025-07-03 AccNo: 0001654954-25-007738 Size: 12 KB

New Form 4 - TENAX THERAPEUTICS, INC. Filed: 2025-07-03 AccNo: 0001654954-25-007737 Size: 9 KB

New Form 4 - TENAX THERAPEUTICS, INC. Filed: 2025-07-03 AccNo: 0001654954-25-007736 Size: 15 KB

New Form 4 - TENAX THERAPEUTICS, INC. Filed: 2025-07-03 AccNo: 0001654954-25-007734 Size: 7 KB

New Form 4 - Cellectar Biosciences, Inc. Filed: 2025-07-03 AccNo: 0001104659-25-065573 Size: 7 KB

New Form 4 - Cellectar Biosciences, Inc. Filed: 2025-07-03 AccNo: 0001104659-25-065572 Size: 7 KB

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

New Form 6-K - CytoMed Therapeutics Ltd Filed: 2025-07-03 AccNo: 0001641172-25-017696 Size: 110 KB

New Form 4 - Cellectar Biosciences, Inc. Filed: 2025-07-03 AccNo: 0001104659-25-065570 Size: 7 KB